Share |
News

Verisante Technology, Inc. Exhibits at Leading Global and Canadian Radiation Technologist Events


June 6, 2012 at 2:00 pm

CEO PRESENTS VERISANTE AURA AT THE CANADIAN INNOVATION SHOWCASE 
AT ISRRT WORLD CONGRESS AND CAMRT ANNUAL GENERAL CONFERENCE

VANCOUVER, BRITISH COLUMBIA - Verisante Technology, Inc. (TSX-V: VRS, OTCQX: VRSEF, Frankfurt: V3T) (the “Company” or “Verisante”), a leader in cancer detection technology, announced today that Thomas Braun, the Company’s President & CEO, has been invited to speak at the International Society of Radiographers & Radiological Technologists (ISRRT) World Congress and the Canadian Association of Medical Radiation Technologists (CAMRT’s) Annual General Conference on June 9, 2012 at 10:30 am.

“Technologists and other frontline health care workers may be the key to alleviating long wait times and bottlenecks that stem from a shortage of overworked specialist physicians,” said Mr. Braun. “The adoption of new technologies such as the Aura™ for skin cancer detection can save the health care system time and money while helping patients with improved outcomes and reduced wait times.”
 
Verisante Aura™ is indicated for use for the evaluation of skin lesions that may be clinically suspicious for melanoma, squamous cell carcinoma and/or basal cell carcinoma when a medical professional chooses to obtain additional information to rule out one of the above conditions before making a final decision to biopsy. With Verisante Aura™ licensed to be used by any medical professional, medical radiation technologists could operate the device and send the results back to doctors, funneling only the most critical cases along to a doctor for biopsy or for referral to a dermatologist. With membership of approximately 12,000, CAMRT members work in over 1000 medical imaging locations in hospitals and private imaging clinics across Canada.

Mr. Braun will present during the Canadian Innovation Showcase, a session of the joint Congress and Conference that highlights Canadian companies who are breaking new ground with revolutionary approaches to diagnostic imaging and therapeutic treatment.

“We are excited to be hosting the Canadian Innovation Showcase, which highlights Canadian ingenuity at the World Congress,” said Chuck Shields, CEO of CAMRT.  “Verisante Aura™ has the potential to be game-changing technology that will no doubt catch the imagination of both our Canadian and international delegates alike.”

Verisante will also have an exhibit at the convention being held at the Sheraton Centre Toronto Hotel from June 7-9, 2012 (Booth #526).

Aura™ is a non-invasive optical system that uses Raman spectroscopy to biochemically analyze the skin, providing immediate and accurate results. The device will help to automate the current process of diagnosis, allowing rapid scanning of the 20 to 40 skin lesions on at-risk individuals, improving patient outcomes and comfort.


Early detection is key to saving the lives of melanoma patients and saving healthcare costs. When melanoma is diagnosed and treated in the earliest stages, the survival rate is 99 per cent and it costs about $1,800 to treat it. In the late stages, the survival rate decreases to 15 per cent, while the cost to treat it increases to $170,000.

Aura™ has been approved for sale in Canada, Europe and Australia.

About The CAMRT

Founded in 1942 by a coalition of provincial associations, the Canadian Association of Medical Radiation Technologists (CAMRT) is Canada’s national professional association and certifying body for medical radiation technologists and therapists across the country.  As the national professional association, the CAMRT is the national body in a partnership with ten provincial associations who share a common membership of approximately 12,000. CAMRT is the national organization for the medical radiation technology profession and has the ability to bring to the table all relevant stakeholders.


For more information on the CMART, please visit:
http://www.camrt.ca/

About Verisante Technology, Inc.

Verisante is a medical device company committed to commercializing innovative systems for the early detection of cancer. The Verisante Aura™ for skin cancer detection and the Verisante Core™ series for lung, colon and cervical cancer detection utilize a proprietary cancer detection platform while the operating software and probe technology are unique to each device. The cancer detection platform was developed by the BC Cancer Agency and tested and refined at the Skin Care Centre at Vancouver General Hospital. This exclusive platform technology allows Verisante to develop and offer a range of
compact, non-invasive cancer detection devices that offer physicians immediate results for many of the most common cancers. The Aura™ has been approved for sale in Canada, Europe and Australia. The Core™ has not yet been approved for sale.

Verisante Aura™ was recently awarded Popular Science Magazine’s “Best of What’s New Award” for 2011, and Verisante Core™ was named one of the top 10 cancer breakthroughs of 2011 by the Canadian Cancer Society. In addition, the Company was named a finalist for the 2011 Regional Awards for New Technology by the Canadian Manufacturers & Exporters and the National Research Council of Canada and named as the year’s top ranking Technology and Life Sciences Company on the TSX Venture 50.

The TSX Venture Exchange has neither approved nor disapproved of the contents of this press release. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Company Contact:
                       
Thomas Braun, President & CEO                   
Verisante Technology, Inc.                   
Telephone: (604) 605-0507                   
Email: info@verisante.com                   
Website:  www.verisante.com                     
Youtube:  www.youtube.com/verisante                 
Twitter: www.twitter.com/verisante
Facebook: www.facebook.com/verisante

Forward Looking Statements

This release contains forward-looking statements, including, but not limited to, statements regarding the future commercialization of medical devices, the market demand for these products and the proprietary protections the Company will obtain with regard to the technology, all of which statements are subject to market risks, and the possibility that the Company will not be able to obtain patent protection or obtain sufficient customer demand. These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties.

  Back to top